Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
-
Published:2022-04
Issue:
Volume:46
Page:101383
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Hernández-Bernal FranciscoORCID, Ricardo-Cobas Maria C., Martín-Bauta Yenima, Navarro-Rodríguez Zadis, Piñera-Martínez Marjoris, Quintana-Guerra Joel, Urrutia-Pérez Karen, Urrutia-Pérez Klaudia, Chávez-Chong Cristina O.ORCID, Azor-Hernández Jorge L., Rodríguez-Reinoso José L., Lobaina-Lambert Leonardo, Colina-Ávila Elizabeth, Bizet-Almeida Jacqueline, Rodríguez-Nuviola Jeniffer, del Valle-Piñera Sergio, Ramírez-Domínguez Mayara, Tablada-Ferreiro Elisangela, Alonso-Valdés Marel, Lemos-Pérez GildaORCID, Guillén-Nieto Gerardo E., Palenzuela-Díaz Ariel, Noa-Romero Enrique, Limonta-Fernández Miladys, Fernández-Ávila Juan M., Ali-Mros Nabil A., del Toro-Lahera Lianne, Remedios-Reyes Rossana, Ayala-Ávila Marta, Muzio-González Verena L.
Funder
Ministry of Public Health
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|